We offer a comprehensive range of monoclonal and polyclonal antibodies to the key leukemia biomarkers, for research purposes as well as diagnostic assay development.
The most common leukemia biomarkers are CD (cluster of differentiation) markers, an extremely diverse series of membrane proteins predominantly expressed on the leukocyte surface. CD markers are mostly useful for classifying white blood cells (WBC) and especially important for diagnosis of lymphomas and leukemias.
The popular CD markers are CD138, also known as Syndecan-1 (SDC-1), a member of the transmembrane heparan sulfate proteoglycan family; CD33 or Siglec-3, a transmembrane receptor expressed on cells of myeloid lineage; and CD52, which is expressed at high density by lymphocytes, monocytes, eosinophils, thymocytes and macrophages.
CD marker-specific antibodies have been widely used for cell sorting, identification, and blood cancer diagnosis. In addition, CD markers have become significantly important for cancer treatment. Some therapeutic antibody drugs have been designed to target cells that have a particular type of CD marker (e.g, rituximab to CD20 for lymphomas and leukemia treatment; alemtuzumab to CD52 for chronic lymphocytic leukemia and T-cell lymphoma treatment).